(Q38206050)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

title

Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

focal segmental glomerulosclerosis

14 March 2020

main subject

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Annette Bruchfeld

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Gert Mayer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Julia Kerschbaum

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Gema Fernandez-Fresnedo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Elion Hoxha

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Christine E Kurschat

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Martin Busch

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Michael Rudnicki

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

15 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Nephrology

14 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

page(s)

322-330

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24751753%20AND%20SRC:MED&resulttype=core&format=json

Adult minimal-change disease: clinical characteristics, treatment, and outcomes.

14 March 2020

cites work

1 reference

Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants

21 January 2018

1 reference

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission

21 January 2018

1 reference

Prevention and treatment of systemic glucocorticoid side effects

21 January 2018

1 reference

Clinical trial of focal segmental glomerulosclerosis in children and young adults

21 January 2018

1 reference

Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome.

21 January 2018

1 reference

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab

21 January 2018

1 reference

Renal involvement in autoimmune connective tissue diseases

21 January 2018

1 reference

Rituximab in idiopathic membranous nephropathy

21 January 2018

1 reference

Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells

21 January 2018

1 reference

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

21 January 2018

1 reference

Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome

21 January 2018

1 reference

Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report

21 January 2018

1 reference

Rituximab in refractory nephrotic syndrome.

21 January 2018

1 reference

Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.

21 January 2018

1 reference

Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis

21 January 2018

1 reference

Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome

21 January 2018

1 reference

Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy

21 January 2018

1 reference

Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.

21 January 2018

1 reference

Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.

21 January 2018

1 reference

Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults

21 January 2018

1 reference

Differential risk of remission and ESRD in childhood FSGS.

21 January 2018

1 reference

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study

21 January 2018

1 reference

Rituximab mediates loss of CD19 on B cells in the absence of cell death

21 January 2018

1 reference

Neutropenia after rituximab treatment: new insights on a late complication

21 January 2018

1 reference

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

21 January 2018

1 reference

Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.

21 January 2018

1 reference

Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?

21 January 2018

1 reference

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.

21 January 2018

1 reference

Focal segmental glomerulosclerosis as a complication of hepatitis B virus infection

21 January 2018

1 reference

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

21 January 2018

1 reference

Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy

21 January 2018

1 reference